Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

John L. Reagan, Rabin Niroula, Jessica McMahon, Pamela Egan, Inna Yakirevich, Mandy Pereira, Ari Pelcovits, Jeannine Margolis, Ashlee Sturtevant, Peter J. Quesenberry, Loren D. Fast

Blood (2023) 142 (Supplement 1): 6874.

https://doi.org/10.1182/blood-2023-177759

Published: 2023

Journal Articles

Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407)

Pamela Egan, Ari Pelcovits, Caitlyn Krar, Stephen Donnelly, Lila Rubin, Rabin Niroula, John L. Reagan, Dana Guyer, Adam J Olszewski, Thomas W LeBlanc

Blood (2023) 142 (Supplement 1): 259.

https://doi.org/10.1182/blood-2023-187645

Published: 2023

Journal Articles

Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma

Adam J Olszewski, Thomas Ollila, Ari Pelcovits, Anna Dorota Chorzalska, John Morgan, Jessica McMahon, Stephen Donnelly, Scott F. Huntington, Matthew Matasar, John L. Reagan, Charles Milrod, Patrycja M. Dubielecka

Blood (2023) 142 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2023-181418

Published: 2023

Journal Articles

Correlation between PFS and OS in FL: Implications for Clinical Trial Endpoint Selection

Charles Milrod, Kang Woo Kim, Thomas Ollila, Adam J Olszewski, Ari Pelcovits

Blood (2023) 142 (Supplement 1): 4395.

https://doi.org/10.1182/blood-2023-177626

Published: 2023

Journal Articles

Enforcing the 4T: Including a Hard Stop 4T Calculator into the Electronic Medical Record for Heparin Induced Thrombocytopenia

Thomas A Ollila, MD, Adam Zayac, MD, Adam J Olszewski, MD, Ross W Hilliard, MD, David Riley, MD, Ari Pelcovits, MD, Matthew R. Austin, MD, Matthew Keane, John L. Reagan, MD

Blood (2018) 132 (Supplement 1): 2442.

https://doi.org/10.1182/blood-2018-99-110375

Published: 2018

Journal Articles

Single-Center Experience of the Utility of a Rapid ADAMTS13 Assay

Peter Barth, MD, Ari Pelcovits, MD, John L Reagan, MD

Blood (2017) 130 (Supplement 1): 3630.

https://doi.org/10.1182/blood.V130.Suppl_1.3630.3630

Published: 2017

NARROW

Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407)

Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma

Correlation between PFS and OS in FL: Implications for Clinical Trial Endpoint Selection

Enforcing the 4T: Including a Hard Stop 4T Calculator into the Electronic Medical Record for Heparin Induced Thrombocytopenia

Single-Center Experience of the Utility of a Rapid ADAMTS13 Assay

Email alerts

ASH Publications

American Society of Hematology

Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407)

Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma

Correlation between PFS and OS in FL: Implications for Clinical Trial Endpoint Selection

Enforcing the 4T: Including a Hard Stop 4T Calculator into the Electronic Medical Record for Heparin Induced Thrombocytopenia

Single-Center Experience of the Utility of a Rapid ADAMTS13 Assay

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only